Working… Menu

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03294083
Recruitment Status : Recruiting
First Posted : September 26, 2017
Last Update Posted : January 19, 2021
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
SillaJen, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : November 2023